Babkova Anna, Robova Helena, Malikova Hana, Drozenova Jana, Pichlik Tomas, Halaska Michael J, Rob Lukas
Department of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, 3rd Medical Faculty, Charles University in Prague, Czech Republic.
Department of Radiology and Nuclear Medicine, University Hospital Kralovske Vinohrady, 3 Medical Faculty, Charles University in Prague, Czech Republic.
Gynecol Oncol Rep. 2024 Oct 16;56:101532. doi: 10.1016/j.gore.2024.101532. eCollection 2024 Dec.
The incidence of cancer during pregnancy is steadily rising because of the postponement of plans for childbearing. One of the most common cancers diagnosed during pregnancy is cervical cancer. Diagnosis of most cases usually occurs in the early stages, but there are still cases of tumors staged IB2 and higher. In these cases, the treatment strategy entails administration of neoadjuvant chemotherapy. However, a universally recognized standardized regimen for neoadjuvant chemotherapy treatment of cervical cancer during pregnancy has yet to be established. The chemotherapy agents used during treatment are known for their fetal adverse effects. The aim of the therapy is to attain full-term pregnancy while minimizing fetal toxicity and decreasing tumor size. In this case report, we present a first-time sequential chemotherapy administration to minimize the cumulative toxicity of individual regimens and demonstrate the benefits for the patient and fetus.
由于生育计划的推迟,孕期癌症的发病率正在稳步上升。孕期最常见的癌症诊断之一是宫颈癌。大多数病例的诊断通常发生在早期阶段,但仍有肿瘤分期为IB2及以上的病例。在这些情况下,治疗策略需要进行新辅助化疗。然而,尚未建立普遍认可的孕期宫颈癌新辅助化疗标准化方案。治疗中使用的化疗药物以其对胎儿的不良影响而闻名。治疗的目的是实现足月妊娠,同时将胎儿毒性降至最低并减小肿瘤大小。在本病例报告中,我们首次进行序贯化疗给药,以尽量减少个体方案的累积毒性,并证明对患者和胎儿的益处。